Biomay Ag

Mead Johnson Nutrition Company

Mjn U.S. Holdings LLC

Worg Pharmaceuticals Co., Ltd.

Margarete Focke-Tejkl

Rudolf Valenta

Susanne Vrtala

Peter Valent

Birgit Linhart

Kuan-Wei Chen

Susanne Spitzauer

Ines Swoboda

Katarzyna Niespodziana

Katharina Marth

Srinita Banerjee

Katharina Blatt

Milena Weber

Dietrich Kraft

Hans Grönlund

Udo Herz

Kerstin Westritschnig

Theresia Popow-Kraupp

Marianne Van Hage

Renate Reininger

Anna Gieras

Raffaela Campana

Ulrike Schulmeister

Heidrun Hochwallner

Rudolph Valenta

Angela Neubauer

Johanna Tinhofer

Eric AF Van Tol

The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Peptide carrier fusion proteins as allergy vaccines

The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Vaccine carrier

The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.

Hypoallergenic hybrid polypeptides for the treatment of allergy

Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Hypallergenic mosaic antigens and methods of making same

Growing community of inventors

Vienna, Austria

Margarete Focke-Tejkl